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ABSTRACT
Long noncoding RNAs (lncRNAs) are major regulators of physiological and disease-
related gene expression, particularly in the central nervous system. Dysregulated 
lncRNA expression has been documented in several human cancers, and their tissue-
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and/or therapeutic agents. Here we show that linc-NeD125, which we previously 
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subgroup. Mechanistically, linc-NeD125 is able to recruit the miRNA-induced silencing 
complex (miRISC) and to directly bind the microRNAs miR-19a-3p, miR-19b-3p and 
miR-106a-5p. Functionally, linc-NeD125 acts as a competing endogenous RNA (ceRNA) 
that, sequestering the three miRNAs, leads to de-repression of their targets CDK6, 
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attenuates their proliferation, migration and invasion.
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system tumours and provides a novel molecular circuit underlying the enigmatic 
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INTRODUCTION
Medulloblastoma is the most common malignant 
paediatric brain tumour [1]. Recent transcriptomics and 
genomics analyses of large human primary tumour cohorts 
assigned MBs to four molecularly distinct subgroups, each 
characterized by specific developmental origins, molecular 
features, and prognoses [1–4]. The best characterized 
WNT and SHH subgroups have been causally linked to 
altered Wingless and Sonic Hedgehog developmental 
cascades, respectively [1]. Larger gaps remain in our 
understanding of the signalling pathways underlying 
Group 3 (G3) and Group 4 (G4) MBs, which account 
for 60% of all prognoses and present the greatest clinical 
challenges [4]. G3, the subgroup with the worst outcomes 
and the highest metastasis rates (75%), is characterized by 
a MYC-activation signature [1]. G4 tumours have a better 
prognosis, and are the most common MBs characterized 
by a neuronal signature with over-representation of genes 
involved in neuronal differentiation and development [1–4]. 
Genomic analyses highlighted subgroup-enriched 
dysregulated genes, the so-called driver genes, altered 
by single nucleotide variants (SNVs) or somatic copy 
number aberrations (SCNAs) [1, 2]. However, driver 
gene expression might also be altered by defects in 
transcriptional [5] or post-transcriptional regulatory 
mechanisms, as those involving microRNAs (miRNAs) [6]. 
Increasing emphasis has been recently placed on 
the potential roles of long noncoding RNAs (lncRNAs) 
as gene expression regulators in human nervous system 
physiology [7]. Aberrant lncRNA expression has been 
documented in neurodevelopmental, neurodegenerative, 
and neuro-oncological disorders [8]. In the latter setting, 
lncRNAs are emerging as critical players: their differential 
expression in gliomas and neuroblastomas has been 
actively investigated [9, 10], but very little is known about 
their roles in MB.
We recently identified a novel human long 
intergenic noncoding RNA (lincRNA), as the host gene 
for miR-125b-1. It is specifically induced during in vitro 
differentiation of neuronal tumour cell lines—hence its 
name: Neuronal Differentiation lncRNA hosting miR-125 
(linc-NeD125) [11]. 
In this study, we  explored the roles it plays in brain 
cancer and discover that linc-NeD125 is an essential 
node in a novel regulatory network in G4 MB, the most 
prevalent and pathogenetically enigmatic class of MBs. 
We demonstrate that, when expressed at the high levels 
found in G4 MBs, linc-NeD125 functions as a competing 
endogenous RNA (ceRNA) that, sequestering miR-19a-3p, 
miR-19b-3p, and mir-106a-5p, de-represses the expression 
of their targets CDK6, MYCN, SNCAIP and KDM6A, 
major driver genes of G4 MB. Remarkably, we revealed a 
role for linc-NeD125 in reducing G4 MB cell proliferation 
and G3 MB cell aggressiveness in vitro.
RESULTS
Linc-NeD125 is targeted by specific miRNAs 
In human BE(2)-C neuroblastoma cells, linc-
NeD125 is localized in the cytoplasm [11]. This finding, 
together with preliminary bioinformatics analyses 
revealing multiple miRNA response elements (MREs) 
throughout its length (Supplementary Table 1), suggested 
that linc-NeD125 might act as a ceRNA. To explore 
this hypothesis, we performed RNA pull-down assays 
in BE(2)-C cells treated with retinoic acid (RA), which 
triggers linc-NeD125 expression approximately 6-fold 
compared to untreated cells [11]. These assays showed 
that linc-NeD125 was associated with Argonaute 2 
(AGO2), a major component of the miRNA-induced 
silencing complex (miRISC) where miRNAs interact 
with their mRNA targets (Figure 1A). Linc-NeD125-
AGO2 interaction was confirmed by crosslinking 
immunoprecipitation (CLIP) experiments (Figure 1B). 
The two approaches demonstrate that linc-NeD125 is 
able to recruit the miRISC, a pre-requisite to function as 
a ceRNA.
To identify the miRNAs possibly associated with 
linc-NeD125 in the miRISC, high-throughput qRT-PCR 
analysis was performed on complexes precipitated from two 
distinct linc-NeD125 pull-down assays. 15 miRNAs were 
found in both experiments (Figure 1C), 6 of which were 
predicted to target linc-NeD125 according to the miRanda 
algorithm (Figure 1D, left panel, and Supplementary 
Table 1). The same tool was used to eliminate 2 of the 6 
miRNAs that could bind the pull-down bait, leaving a short 
list of 4 miRNAs—namely miR-19a-3p, miR-19b-3p, miR-
106a-5p and miR-191-5p—which are specifically bound by 
linc-NeD125 (Figure 1D, right panel).
Linc-NeD125 is expressed in MBs and 
upregulated in G4 subgroup
The experiments in tumour-derived neuronal cells 
provided evidence that linc-NeD125 is a potential ceRNA. 
Given the increasing evidence for the involvement of 
lncRNAs as ceRNAs in neuronal cancer-associated 
networks [12], we asked whether linc-NeD125 may play 
this role in MBs. Taking advantage of a large number 
of available human specimens, we evaluated linc-
NeD125 expression in a cohort of 51 primary tumours 
(Supplementary Table 2), representing all four MB 
subgroups in proportions reflecting their incidence in the 
population [1]. As shown in Figure 2A, linc-NeD125 was 
expressed in all subgroups and significantly upregulated 
(20-fold increase on average) in G4 MB, compared to 
normal cerebellum. Levels found in G4 tumors were 
approximately twice as high as those in WNT MBs and 
roughly 20 times those of the SHH and G3 tumours. 
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Figure 1: Identification of linc-NeD125 interactors. (A) Linc-NeD125 RNA pull-down assay in RA-treated BE(2)-C cells. Upper 
panel: Western blot analysis of AGO2 and GAPDH in Input (Inp), linc-NeD125 probe-bound (α-125) and non specific probe-bound 
(CTRL) protein fractions. Middle panel: levels of Linc-NeD125 and Gapdh RNAs in Inp, α-125 and CTRL RNA fractions. RT- sample 
was used as negative control. Lower panel: fractionation on denaturing agarose gel of specific (α-125) and unspecific (CTRL) biotinylated 
probes. (B) AGO2 CLIP assay. Upper panel: RNA analysis from RA-treated BE(2)-C cells of Linc-NeD125 or Gapdh as negative control 
in Input fraction (Inp) and extracts immunoprecipitated with AGO2 (IP) or IgG (IgG). Lower panel: Western blot of AGO2 in AGO2- (IP) 
or IgG- (IgG) immunoprecipitated cell extracts, or in Input sample (Inp) as control. (C) Levels of miRNAs associated with linc-NeD125 
in pull-down assays #1 (white bars) and #2 (black bars). Common hits are bolded. Enrichments refer to control samples (CTRL), set as 1. 
Data are normalized to ath-miR159a levels and expressed as arbitrary units (AU). (D) Left panel: scheme summarizing the filtering process 
identifying specific linc-NeD125 interactors. Right panel: number and positions of miR-19a-3p, miR-19b-3p, miR-106a-5p, miR-191a-5p 
MREs on linc-NeD125 sequence. Locations of the 6 MREs on linc-NeD125 are schematised below.
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miR-19a-3p, miR-19b-3p and miR-106a-5p 
repress G4 MB driver gene expression 
To determine linc-NeD125 contribution to G4 
MB, we checked whether genes relevant for this tumour 
subgroup were specific targets for the bound miRNAs. We 
initially assessed miRNA occurrence in G4 primary tumors. 
As shown in Figure 2B, only miR-19a-3p, miR-19b-3p, and 
miR-106a-5p were significantly overexpressed in tumour 
specimens, with 2- to 4-fold increases over control levels.
Subsequent in silico analysis showed that the G4 
driver genes, namely the proto-oncogenes CDK6 and 
MYCN, the α-synuclein-interacting protein SNCAIP, 
the histone H3 lys27 demethylase KDM6A, the H3K4 
methyltransferase MLL3 and the zinc finger protein 
ZMYM3 [1], share a significant number of predicted 
targeting microRNAs (Supplementary Table 3), suggesting 
a coordinated regulation. Among those, we found that the 
microRNAs bound by linc-NeD125, miR-19a-3p, miR-
19b-3p and miR-106a-5p, were predicted to pleiotropically 
repress five G4 driver genes (Figure 2C).
To validate this prediction we used, as an in vitro 
model system, the D283 Med cells. They are G3-derived 
MB cells [13] that show low levels of linc-NeD125 
(Figure 2D) allowing us to upregulate its expression as 
observed in G4 tumours. 
Given the high expression levels of miR-19a-
3p, miR-19b-3p and miR-106a-5p in D283 Med cells 
(Figure 2E), miRNA loss-of-function experiments were 
performed. Co-transfection of Locked Nucleic Acids 
(LNAs) against the three miRNAs did not alter linc-
NeD125b levels (Figure 3A, left panel), while caused 
an increase of CDK6, MYCN, SNCAIP and KDM6A 
protein levels (ranging from ~1.4 to ~2-fold over LNA-
control treated cells) (Figure 3A, middle and right panels), 
demonstrating that the corresponding genes are targets of 
the three miRNAs bound by linc-NeD125.
Further demonstration that the three miRNAs together 
are able to specifically interact with CDK6, MYCN, SNCAIP 
and KDM6A mRNAs derived from luciferase reporter 
assays. As schematized in Figure 3B (left panel), portions 
of their 3′UTRs were cloned downstream of the r-luc ORF 
and expressed in D283 Med cells together with scramble 
or miRNA targeting LNAs. Histograms in Figure 3B (right 
panels) show an increase of luciferase activity indicating the 
specificity of the three  miRNA interaction.
Linc-Ned125 de-represses G4 MB driver gene 
expression by sequestering miR-19a-3p,  
miR-19b-3p, and miR-106a-5p 
To explore linc-NeD125 involvement in the 
control of G4 MB driver genes and the possibility that it 
is mediated by its miRNA sponge activity, we designed 
constructs expressing mature wild type linc-NeD125 
(Linc-125) or a mutant derivative defective in miRNA 
binding activity (mLinc-125) (Supplementary Figure 1). 
The latter was planned by introducing single point 
mutations in MRE sites corresponding to miRNA seed 
positions 4 and 5 [14]. Importantly, we ensured that none 
of the mutations created new miRNA-binding sites.
To verify the specificity of miRNA-linc-NeD125 
interaction, we cloned the wild type and mutant linc-
NeD125 into luciferase reporter vectors (Figure 4A, left 
panel) and transfected them into D283 Med cells, along 
with the LNAs complementary to miR-19a-3p, miR-
19b-3p, and miR-106a-5p. As shown in Figure 4A (right 
panel), cells transfected with the LNAs and wild type linc-
NeD125 (Luc/Linc-125) exhibited increased luciferase 
activity (1.5-fold over controls), but no change was 
observed in cells transfected with the mutant transcript 
(Luc/mLinc-125). These results confirm the specificity of 
the miRNA/linc-NeD125 interaction and the inability of 
the mutant transcript to bind the three miRNAs. 
For functional analyses, the wild type and mutant 
linc-NeD125 sequences were cloned into an expression 
vector (Figure 4B, left panel) and transfected in D283 
Med cells. As shown in Figure 4B (right panel) the two 
transcripts were overexpressed at levels comparable to 
those characterizing primary G4 MBs. Their ectopic 
expression had no effect on the levels of miR-19a-3p, 
miR-19b-3p, or miR-106a-5p (Supplementary Figure 2), 
indicating that linc-NeD125 does not regulate their 
abundance [15]. G4 driver gene mRNA levels were also 
unaltered (Figure 4C, left panel), suggesting that their 
regulation by the three miRNAs occurs mainly at the 
translational level (See Figure 3A, middle panel). In 
contrast, driver gene protein products were significantly 
increased by ectopic expression of wild type linc-NeD125 
(1.5- to 2-fold increases), as compared with untreated 
controls (Figure 4C, middle and right panels). No any 
effect was produced by overexpression of the mutant linc-
NeD125. Complementary loss-of-function experiments 
were carried out in a recently reported G4 in vitro model 
system, the CHLA-01-MED cell line [16], where linc-
NeD125 is expressed at higher levels compared to 
D283 Med cells (Figure 4D, left panel). We found that 
knockdown of the endogenous linc-NeD125 in CHLA-01-
MED cells (Figure 4D, right panel) caused a significant 
decrease of the four driver gene protein products 
(Figure 4E), and that this is accompanied by a significant 
reduction of cell proliferation (Figure 5A, upper panel) and 
of the proliferation marker KI-67 (Figure 5A, lower panel).
Collectively, these results demonstrate that linc-
NeD125 controls the in vitro expression of four genes 
known to drive G4 MB, i.e. CDK6, MYCN, SNCAIP, and 
KDM6A, by competing with their transcripts for binding 
to miR-19a-3p, miR-19b-3p and miR-106a-5p. 
Linc-NeD125 impairs in vitro cell proliferation, 
migration and invasion of G3 MB cells 
We asked whether the observed linc-NeD125-
mediated derepression of specific G4 MB driver genes 
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in a G3 MB genetic background led to any phenotypic 
consequence.
We assessed G3-derived D283 Med cells’ 
capacities for proliferation, migration, and invasion after 
overexpression of wild type or mutant linc-NeD125 
(Figure 5B), at the high levels observed in primary G4 
tumors. Unexpectedly, the results of BrdU labelling assay, 
which measures DNA replication rates (Figure 5C), and 
the analysis of the proliferation marker KI-67 (Figure 5D) 
showed that cell proliferation was significantly reduced 
by wild type linc-NeD125 (a decrease of approximately 
30%) but was unaffected by the mutant. Migration 
(Figure 5E) and invasion (Figure 5F) were also reduced 
(by approximately 40%) in linc-NeD125 overexpressing 
cells, but no effects were seen in cells expressing the 
mutant transcript. To confirm that linc-NeD125 biological 
function depends on its ability to inhibit miRNA activity, 
we analyzed D283 Med cell proliferation (Figure 6A 
and 6B), migration (Figure 6C) and invasion (Figure 6D) 
upon LNA-mediated miRNA sequestration. A decrease 
Figure 2: Expression of linc-NeD125 and interacting miRNAs in primary MBs and D283 Med cells. (A) Linc-NeD125 
expression in 51 primary MBs (coloured dots; subgroup distribution: WNT = 8; SHH = 10; G3 = 13; G4 = 20) and 10 normal cerebella (AD, 
black dots). Results (means+/−s.d.) expressed in arbitrary units (AU) are normalized to the mean value of 4 housekeeping genes (*p < 0.05). 
(B) MiR-191a-5p, miR-19a-3p, miR-19b-3p and miR-106a-5p expression in G3 (yellow dots) or G4 MBs (green dots) vs normal cerebella 
(AD, black dots). Results (means+/−s.d.) expressed in arbitrary units (AU) are normalized to levels of U6 snRNA (*p < 0.05). (C) Predicted 
miRNA target sites within the 3′UTR of G4 MB driver genes. (D) Linc-NeD125 is under-expressed in D283 Med cells (gray bar) compared 
to normal cerebella (AD, white bar). Data analysis as in (A). (E) Up-regulation of miR-19a-3p, miR-19b-3p and miR-106a-5p in D283 Med 
cells (gray bars) compared to normal cerebella (white bars, AD). Results expressed as in (B).
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of about 40% of cell proliferation and a 70% decrease of 
migration and invasion of D283 Med cells were observed. 
Furthermore, to demonstrate that linc-NeD125 
action is directed towards the G4 driver genes CDK6, 
MYCN, SNCAIP, and KDM6A, linc-NeD125 was 
ectopically expressed in D283 Med cells while repressing 
their expression. Figure 7 shows that siRNA-mediated 
silencing of the driver genes prevents linc-NeD125 
from affecting cell proliferation (Figure 7A), migration 
(Figure 7B) and invasion (Figure 7C).
These results demonstrate that linc-NeD125 ectopic 
expression in D283 Med cells can effectively attenuate the 
G3 MB cell capacities for proliferation, migration, and 
invasiveness, and that these effects are mediated by linc-
NeD125 sponge activity. 
DISCUSSION
Roughly 60% of MBs belong to G3 and G4. Both 
are associated with relatively unfavourable outcomes 
Figure 3: Interaction of miR-19a-3p, miR-19b-3p and miR-106a-5p with G4 driver genes. (A) miRNAs regulate driver gene 
expression. Left panel: linc-NeD125 expression in D283 Med cells transfected with LNA inhibitors targeting miR-19a, miR-19b and miR-106a 
(LNA miRs, gray bar) or with scrambled LNA (LNA CTRL, white bar). Middle panel: Western blot analysis of five G4 MB driver gene 
protein products in D283 Med cells transfected with LNAs against miR-19a, miR-19b, miR-106a (LNA miRs) or with scrambled LNA 
(LNA CTRL). GAPDH: loading control. Right panel: protein level densitometric analysis. Results (means+/−s.d.) from three biological 
replicates (*p < 0.05) are expressed in arbitrary units (AU). (B) Luciferase assays in D283 Med cells. Left panel: representation of luciferase/
driver gene 3′UTR reporter constructs. MREs are indicated as thick lines, miRNAs as thin lines. For each miRNA, number of MREs are 
reported in brackets. Right panels: activity of Renilla luciferase expressed from the constructs shown in the left panel, in the presence of 
specific LNAs (LNA miRs, gray bars) or scrambled LNA (LNA CTRL, white bars). Renilla luciferase activity (means+/−s.d. from three 
biological replicates) expressed as arbitrary units (AU), is normalized over firefly luciferase activity (internal control) and referred to CTRL 
sample, set as 1.
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Figure 4: Linc-NeD125 overexpression and downregulation in MB cells. (A) Luciferase assays in D283 Med cells. Left panel: 
representation of wild type (Luc/Linc-125) or mutant (Luc/mLinc-125) luciferase/linc-NeD125 reporter constructs. Wild type MREs are 
indicated as thick lines, miRNAs as thin lines, point mutations as dots (See Supplementary Figure 1 for mutant sequences). Right panel: 
activity of Renilla luciferase expressed from wild type (bars Luc/Linc-125) or mutant construct (bars Luc/mLinc-125) in the presence of 
LNA inhibitors (LNA miRs, gray bars) or scrambled control LNA (LNA CTRL, white bars). Renilla luciferase activity (means+/−s.d. from 
three biological replicates), expressed as arbitrary units (AU), is normalized over firefly luciferase activity (internal control) and referred 
to wild type CTRL sample, set as 1. (B) Linc-NeD125 overexpression in D283 Med cells. Left panel: constructs are represented as in (A). 
Right panel: levels of linc-NeD125 in D283 Med cells transfected with Linc-125 (gray bar), mLinc-125 (black bar) or with the empty vector 
(CTRL, white bar). Results, expressed as arbitrary units (AU) (means+/−s.d.) are normalized to the mean value of 4 housekeeping genes 
(*p < 0.05) and referred to CTRL sample, set as 1. (C) Left panel: expression levels of CDK6, MYCN, SNCAIP, KDM6A and MLL3 mRNAs 
in D283 Med transfected with constructs expressing wild type (Linc-125) or mutant linc-NeD125 (mLinc-125). Middle panel: Western blot 
of CDK6, MYCN, SNCAIP, KDM6A and MLL3 proteins in D283 Med cells transfected as described in left panel. GAPDH: loading control. 
MLL3 analysis was included as a negative control. Right panel: protein level densitometric analysis. Results are expressed as means+/−s.d. 
from at least three biological replicates (*p < 0.05) and referred to CTRL samples set as 1. MiRNA levels evaluated in the same conditions 
are reported in Supplementary Figure 2. (D) Left histogram: comparative qRT-PCR analysis of Linc-NeD125 in D283 Med (white bar) and 
CHLA-01 Med cells (black bar). Right histogram: levels of linc-NeD125 in CHLA-01 Med cells transfected with Linc-NeD125 esiRNA (esi 
Linc-125, gray bar) or scrambled esiRNA (esi CTRL, white bar). Data analysis as in (C). (E) Left panel: Western blot of CDK6, MYCN, 
SNCAIP, and KDM6A proteins upon transfection of Linc-NeD125 esiRNA (esi Linc-125, gray bars) or scrambled esiRNA (esi CTRL, white 
bars) in CHLA-01 cells. ACTIN: loading control. Right panel: protein level densitometric analysis. Data analysis as in (C).
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(particularly G3), and targeted therapies are at their 
infancy. The pathogenesis of G3 and G4 is still poorly 
defined: their development cannot be adequately explained 
by SCNAs and SNVs alone, and it could depend on 
additional mechanisms operating widely at the epigenetic 
and/or post-transcriptional levels.
Our findings delineate a novel ceRNA network 
headed by linc-NeD125 (Figure 8), which significantly 
contributes to the dysregulation of four critical G4 MB 
driver genes. Linc-NeD125 functions as a natural miRNA 
sponge, competitively binding and sequestering three 
endogenous miRNAs—miR-19a-3p, miR-19b-3p and 
miR-106a-5p—whose targets include CDK6, MYCN, 
SNCAIP, and KDM6A transcripts (Figure 8). This is the 
first report of a lncRNA-based ceRNA network associated 
with neuronal cancer [12], and a new example of a single 
RNA sponge simultaneously controlling a large number of 
co-regulated targets in cancer [17, 18].
CeRNA activity has been described in different 
experimental systems and attributed to several RNA 
species, including lncRNAs, pseudogenes, circular 
RNAs, and mRNAs [19]. Different models predict the 
requirement of near-equimolarity among ceRNA network 
components for regulation to occur [20]. However, natural 
regulatory networks are likely to be more complex owing 
to physiological and pathological variations (transient 
enrichment, local concentration) in RNA levels. Our data 
indicate that linc-NeD125 behaves as a miRNA sponge in 
G4 MBs, where its expression is approximately 20-fold 
higher than that found in normal cerebellar tissues. This 
Figure 5: Effects of linc-NeD125 overexpression or knockdown on MB cell properties. (A) BrdU assay of CHLA-01 Med 
cells transfected with Linc-NeD125 esiRNA (esi Linc-125, gray bar) or scrambled esiRNA (esi CTRL, white bar). Results (means+/−s.d.) 
are expressed in percentage of BrdU positive cells from three biological replicates (*p < 0.05). (B) Western blot analysis of KI-67 from 
cells treated as in (A). GAPDH: loading control. (C) BrdU assay of D283 Med cells transfected with Linc-125 (gray bar), mLinc-125 (black 
bar) or empty vector (CTRL, white bar). Details as in (A). (D) Western blot analysis of KI-67 from cells treated as in (C). GAPDH: loading 
control. (E) Cell migration. D283 Med cells transfected as in (C) were Hoechst-stained and counted after a 24 h-migration. Histogram 
represents the number of migrating cells from three biological replicates, relative to CTRL set as 1. Pictures of representative fields are 
reported aside. (F) Cells invasion. Details as in (E).
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conclusion derives from gain-of-function experiments in 
D283 Med cells, which exhibit the molecular features of 
primary G3 MB [13], including linc-NeD125 expression 
levels lower than those found in G4 tumors. This makes 
them a highly suitable system for mechanistic studies 
of linc-NeD125 function. Remarkably, linc-NeD125 
overexpression in D283 Med cells at levels comparable 
to G4 tumors elicited the de-repression of multiple G4 
MB driver genes, targets of the sponged miRNAs. Linc-
NeD125 sponge activity is confirmed by the evidence 
that overexpression of its mutant derivative, carrying 
microRNA target sites disrupted at specific positions in 
Figure 6: Effects of miR-19a-3p, miR-19b-3p, miR-106a-5p inhibition on D283 Med cell properties. (A) BrdU assay of 
D283 Med cells transfected with LNAs against miR-19a-3p, miR-19b-3p, miR-106a-5p (LNA miRs, gray bar) or with a scrambled LNA 
(LNA CTRL, white bar). Results (means+/−s.d.) are expressed in percentage of BrdU positive cells of three biological replicates (*p < 0.05). 
(B) Western blot analysis of KI-67 from cells treated as in (A). GAPDH: loading control. (C) Cell migration. D283 Med cells transfected as 
in (A) were Hoechst-stained and counted after a 24 h-migration. Histogram represents the number of migrating cells from three biological 
replicates, relative to CTRL set as 1. Pictures of representative fields are reported aside. (D) Cells invasion. Details as in (C).
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the seed, fails to alter G4 MB driver gene expression. 
Unlike commonly used deletion mutants, this designed 
site-specific mutant created no novel miRNA binding 
sites and minimized changes in linc-NeD125 sequence 
and structure, two features crucial for noncoding RNA 
activity. Notably, the complementary linc-NeD125 loss-
of-function experiment carried out in the G4 MB cell line 
CHLA-01-MED confirmed its role as a ceRNA regulating 
G4 driver genes. This, together with the decrease of G4 
cell proliferation upon linc-NeD125 knockdown, indicates 
it may function as an oncogene in G4 MB tumours. In vivo 
studies are required to address this point.
The phenotypic upshot of linc-NeD125 
overexpression in a G3 cell model is the acquisition of 
specific G4 molecular features, namely an increase of 
the G4 driver gene protein products. Unexpectedly, this 
Figure 7: Effects of driver gene downregulation and linc-NeD125 overexpression on D283 Med cell properties. (A) 
BrdU assay of D283 Med cells transfected with siRNAs against CDK6, MYCN, SNCAIP, and KDM6A (dark gray bar) or with the plasmid 
overexpressing Linc-NeD125 (Linc-125, light gray bar) or with siRNAs and Linc-125 together (black bar), compared to cells transfected 
with scrambled siRNAs and empty vector (CTRL, white bar). Results (means+/−s.d.) are expressed in percentage of BrdU positive cells of 
three biological replicates (*p < 0.05). (B) Cell migration. D283 Med cells transfected as in (A) were Hoechst-stained and counted after a 
24 h-migration. Histogram represents the number of migrating cells from three biological replicates, relative to CTRL set as 1. Pictures of 
representative fields are reported below. (C) Cells invasion. Details as in (B).
Oncotarget31013www.impactjournals.com/oncotarget
was accompanied by a significant attenuation of the high 
capacity for proliferation, migration and invasion that 
characterises the high metastatic G3 cells, making them 
G4-like cells for these capacities. Although the underlying 
mechanism, dependent on linc-NeD125 ceRNA function, 
is still unknown, we speculate that it might be related to 
the neuronal signature that specifically marks G4 MB [1] 
and that is possibly responsible for the less aggressiveness 
of this tumour subgroup. In fact, while group 3 has the 
worst prognosis with less than 50% 5-year survival, group 
4 has an about 75% 5-year overall survival [1]. In light of 
its ability to attenuate the in vitro aggressiveness of the 
metastatic G3 MB cell line and the proliferation of G4 MB 
cells, linc-NeD125 mode of action merits deeper study for 
possible therapeutic applications. 
In conclusion, post-transcriptional miRNA-mediated 
crosstalk between linc-NeD125 and protein-coding RNAs 
appears to play a significant role in G4 MB tumorigenesis. 
Linc-NeD125 may be a novel driver gene operating upstream 
of the already identified G4 protein-coding driver genes, 
and/or it might keep high the levels of driver gene products 
participating in the maintenance of cancer cell identity.
The results of our study highlight linc-NeD125 as a 
key player in G4 MB driver gene network and as a novel 
member of the small but growing list of lncRNAs implicated 
in human cancerogenesis via the ceRNA mechanism.
MATERIALS AND METHODS
Human tissue samples
Surgical specimens of 51 primary MBs were 
collected at the Bambino Gesù Children’s Hospital 
in Rome (2011–2015). Clinical features and sample 
treatments are detailed in Supplementary Table 2 and 
Supplementary Materials and Methods.
MB molecular subgrouping 
Molecular characterization of the 51 tumours was 
performed as previously described [21]. Details of molecular 
characterization are shown in Supplementary Table 4.
Cell lines 
BE(2)-C, D283 Med and CHLA-01 Med cells were 
cultured according to the recommended conditions (ATCC). 
Details are in Supplementary Materials and Methods. 
Plasmids
pcDNA3.1-Linc-NeD125: the wild-type version was 
PCR-amplified from cDNA generated from 4 day RA-
treated BE(2)-C cells with the oligolucleotides UpBam 
and DownNot1, and inserted between the BamHI and NotI 
restriction sites of the pcDNA3.1+ vector. The mutant 
version was derived by the QuikChange II Site-Directed 
Mutagenesis Kit (Agilent), using the oligonucleotides 
Mut1-Mut4. psiCheck2-Linc-Ned125: wild type version 
was PCR-amplified from pcDNA3.1-Linc-NeD125 with 
the oligonucleotides UpXho and DownNot1. The mutant 
was derived from the wild type, as described above. 
pEZX-MYCN and pEZX-SNCAIP 3’UTR luciferase 
reporter constructs were purchased from GeneCopoeia. 
psiCheck2-KDM6A and psiCheck2-CDK6: KDM6A and 
CDK6 3′UTRs were PCR amplified from genomic DNA 
with the oligonucleotides UpXho2 and DownNot2 or 
UpXho3 and DownNot3, respectively. Oligonucleotides 
are listed in Supplementary Table 5.
Figure 8: A model of linc-NeD125-dependent ceRNA network in G4 MB. Upregulation of linc-NeD125 (open arrow) represses 
miRNA activity (blocked lines) causing driver gene derepression (black arrows). 
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Overexpression and knockdown experiments in 
D283 Med and CHLA-01 Med cells
Plasmids were transfected (or co-transfected) with 
Lipofectamine 2000 (Thermo Scientific). LNAs targeting 
miRNAs (Exiqon) and siRNAs targeting G4 driver 
genes (Qiagen) were transfected with Hyperfect reagent 
(Qiagen) at a concentration of 20 nM (each molecule). 
EsiRNAs (SIGMA Aldrich) were used as in [11] for linc-
NeD125 knockdown.
Expression analyses
Purified RNA was retrotranscribed and analyzed on 
a ViiA™7 Real-Time PCR System (Applied Biosystems-
Thermo Scientific) using best-coverage TaqMan gene 
expression assays specific for each mRNA. MiRNA 
expression levels were measured with miRNA-specific 
Taqman assays (Thermo Scientific) and results were 
normalized vs the endogenous control (snRNA U6). Linc-
NeD125 RNA detection was performed using the ViiA™7 
Real-Time PCR System with primers 125 FW and 125 
REV and normalized to Gapdh levels.
Western blot and antibodies
Western blots were performed as previously 
described [22], using the antibodies reported in 
Supplementary Materials and Methods.
RNA pull-down assay
Linc-NeD125 pull-down assays were performed 
with biotinylated antisense specific or unspecific probes on 
extracts from RA-treated BE(2)-C cells, as described [11]. 
Proteins and RNA were extracted from eluted samples and 
analyzed by Western blot, RT-PCR or qRT-PCR. 
Crosslinking immunoprecipitation (CLIP) assay
Extracts from RA-treated BE(2)-C cells were 
immunoprecipitated with 5 μg of AGO2 antibody 
(Ascenion, 11A9), as described [11]. After extraction using 
the miRNeasy Mini Kit (Qiagen), immunoprecipitated 
RNA was retrotranscribed and analyzed by RT-PCR using 
specific primers for linc-NeD125 or Gapdh mRNAs. 
Protein levels were analyzed by Western blot.
High-throughput miRNA analysis
MiRNA enrichment was profiled by Applied 
Biosystems TaqMan® microRNA Arrays A and B (Applied 
Biosystems), according to the manufacturer’s instructions. 
Details in Supplementary Materials and Methods.
Luciferase assays
D283 Med cells were co-transfected with constructs 
expressing Luc/Linc-125, Luc/mLinc-125, Luc/MYCN, 
Luc/SNCAIP, Luc/CDK6 or Luc/KDM6A transcripts 
(plasmid: 0.05 ng/ml of transfection mix) and LNAs 
(20 nM/each, specific or scrambled). 48–72 hours after 
transfections, cells were lysed and luciferase activity was 
measured in Glomax Multi+ Detection System (Promega), 
using Dual-Luciferase Reporter Assay System (Promega).
Cell proliferation, migration and invasion assays 
Cell proliferation was evaluated by 
Bromodeoxyuridine (BrdU) assay. Migration and invasion 
assays were performed in Boyden chambers with non-
coated or Matrigel-coated membranes, respectively. 
Cells on the lower surface of the membranes were fixed, 
Hoechst-stained and counted under microscope. Details in 
Supplementary Materials and Methods.
Statistical analysis
Results are expressed as means+/−s.d. from an 
appropriate number of experiments indicated in Figure 
Legends. Statistical differences were analyzed by the 
Mann–Whitney U-test for non-parametric values using 
the GraphPad_Prism software. An adjusted p-value < 0.05 
was considered as statistically significant.
Bioinformatics analysis
miRNA/target interactions were predicted with 
miRanda 3.3 and microRNA.org database. Linc-NeD125 
mutant derivative was designed according to miRanda 3.3. 
Details in Supplementary Materials and Methods.
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